Newsfeeds - Spark Newswire

2 minute read

Aditxt Earlier Announced Its Psoriasis Clinical Program Will Now Be Slated For 2022 Instead Of Dec. 2021

Today, 7:58 AM

Psoriasis First-in-Human (Phase I/IIa) program is slated for 2022 Type 1 Diabetes and Skin Allografting are planned to enter clinical trials in 2022 Pre-clinical investigational work has started in Multiple

ADTX

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s After-Market Session

By Benzinga Insights

Today, 7:58 AM

Gainers Eyegate Pharmaceuticals (NASDAQ:EYEG) stock increased by 25.64% to $3.92 during Monday's after-market session. The company's market cap stands at $27.8 million.

ADTX

1 minute read

Movers

12 Health Care Stocks Moving In Monday’s After-Market Session

By Benzinga Insights

Today, 7:58 AM

Gainers

ADTX

1 minute read

Aditxt’s COVID-19 Test To Include Specific Antibodies To Detect Individual Immune Response; Shares Rise

By Vandana Singh

Today, 7:58 AM

Aditxt Inc (NASDAQ:ADTX) has announced enhancements to its AditxtScore for COVID-19 to include a high-sensitivity neutralizing antibody diagnostic. The multi-dimensional immune…

ADTX

2 minute read

News

Aditxt Launches High-Sensitivity Neutralizing Antibody Test to Detect Individual Immune Response to COVID-19

By Benzinga Newsdesk

Today, 7:58 AM

Aditxt, Inc. (“Aditxt”) (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced enhancements to its AditxtScore™ for COVID-19. A

ADTX

Latest news

Aditxt Earlier Announced Its Psoriasis Clinical Program Will Now Be Slated For 2022 Instead Of Dec. 2021

12 Health Care Stocks Moving In Monday’s After-Market Session

12 Health Care Stocks Moving In Monday’s After-Market Session

Aditxt’s COVID-19 Test To Include Specific Antibodies To Detect Individual Immune Response; Shares Rise

Aditxt Launches High-Sensitivity Neutralizing Antibody Test to Detect Individual Immune Response to COVID-19